NCT07845201Not yet recruiting
Intermediate Outcomes of HFrEF Patients on Guideline-Directed Medical Therapy
Intermediate Outcomes of Patients With Heart Failure With Reduced Ejection Fraction (HFrEF) in View of Current Guideline-Directed Medical Therapy
Source: ClinicalTrials.gov · Last updated 30 Sept 2026
Brief summary (registry, in English)
This prospective observational study aims to evaluate intermediate clinical, renal, and functional outcomes in patients with heart failure with reduced ejection fraction treated with contemporary guideline-directed medical therapy over a 6 to 12 month follow-up period.
- Status (registry)
- Not yet recruiting
- Study type
- Observational
- Enrollment
- 250 (estimated)
- First submitted
- 22 Sept 2026
- Start date
- 26 Sept 2026
- Primary completion date
- 26 Sept 2027
- Lead sponsor
- Assiut University
- Diseases
- Heart failure
- NCT number
- NCT07845201
What you commit to
- Study type: Observational
- Planned participants: 250
- From 26 Sept 2026 to the primary completion date, 26 Sept 2027
- No sites listed in no country
- Visits and tests: ask the trial team, the registry does not list them
Built from the registry fields of ClinicalTrials.gov. It describes the study, not your situation.
Who cannot take part
Copied verbatim from ClinicalTrials.gov and grouped by topic. Only the trial team decides who can take part.
Other illness
- \- Acute decompensated heart failure requiring intravenous inotropes at enrollment
- End-stage renal disease on dialysis
- Severe primary valvular disease requiring immediate intervention
- Life expectancy less than 6 months due to non-cardiac illness
Lab values
- eGFR less than 20 mL/min/1.73 m² at baseline
Who the study is looking for
- Age 18 years or older
- Diagnosis of chronic HFrEF with LVEF ≤ 40% documented by echocardiography
- Stable on or planned initiation of guideline-directed medical therapy
- Ability to provide informed consent
Age in the registry: 18 years to - · Sex: All · Does not accept healthy volunteers
This page is information, not medical advice. Discuss any trial with your doctor.